Foundation Medicine gets $25M Round for Genetic Sequencing

By John Carroll Cambridge, MA-based Foundation Medicine has raised $25 million in a Series A, coming out of stealth mode with bold plans to create clinical lab tests that can use the latest in genetic sequencing technology to identify personalized cancer therapies for patients. As expected, , who landed as an entrepreneur-in-residence with Third Rock Ventures …

16th April 2010
Deals, Financings, New Technology, Personalized Medicine
READ MORE

Test Could ID Who Should Get MS Drugs

By Tracey Staton In another potential step toward personalized medicine, researchers have developed a test that predicts whether multiple sclerosis patients will respond to beta interferon drugs. The $6 billion drug class–which includes Biogen Idec’s Avonex, Merck KGaA’s Rebif, and Bayer’s Betaferon–works in patients with one subtype of MS, but not in the other, researchers …

4th April 2010
Personalized Medicine
READ MORE